entertainment -WSS

entertainment

author：entertainment 2025-09-27 09:44:27 - browse：22898

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Mark Cuban is blaming the wrong people for high drug costs

knowledge

WSS

Key House Republican on health care plans exit from Congress

Judge sides with young activists in first

KalVista pill reduced swelling 'attacks' caused by genetic disease

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Bird flu researchers hone in on Finland’s mink farms

Treatments for cramps don't cut it. Why aren't there better options?

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Apple is now the first public company to be valued at $3 trillion

Judge sides with young activists in first

The cancer drug shortage isn’t new — and neither are the solutions

PhRMA lawsuit over Medicare drug price negotiation tossed

New air purifier tech could be key to improving indoor air quality

Idaho college killings prosecutors challenge defense's grand jury claims

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The Readout: Gilead, Bernie Sanders, and other pharma news

Tori Bowie and the unacceptable rates of Black maternal death

Key House Republican on health care plans exit from Congress

focus

Senators start work on Medicare physician payment reform

Illinois Supreme Court finds assault weapons ban constitutional

Readout LOUD podcast: How biotech is using artificial intelligence

Surge in Apellis stock fueled by confidence in safety of its eye drug

Judge sides with young activists in first

Doctors' information doesn't help them choose wisely when sick

hotspot

knowledge

focus

focus